

PROGRAMME – THURSDAY 27 NOVEMBER, 2014

10.00 onwards		Registration and coffee		
Session 1		Lipids and vascular disease	Chair:	S. Thom, London
11.00-11.05		Chairman's welcome		
11.05-11.25	1.1	Atherosclerosis related disease: size of the problem		N.R. Poulter, London
11.25-11.35		Discussion		
11.35-11.55	1.2	Lipids and lipoproteins: what you need to know		J.P. Miller, Manchester
11.55-12.05		Discussion		
12.05-12.25	1.3	Biology of atherosclerosis		J. Halcox, Cardiff
12.25-12.35		Discussion		
12.35-13.45		Lunch		
Session 2		Lipid disorders and guidelines	Chair:	P. Sever, London
13.45-14.05	2.1	Primary hyperlipidaemias		J.P. Miller, Manchester
14.05-14.15		Discussion		
14.15-14.35	2.2	Lipid management, guideline update		P. Flynn, Cambridge
14.35-14.45		Discussion		
14.45-15.05	2.3	Lipids and peripheral arterial disease		R. Bulbulia, Oxford
15.05-15.15		Discussion		
15.15-15.45		Tea		
Session 3		Lipid management	Chair:	N. Poulter, London
15.45-16.05	3.1	Review of current second line drugs		A.S. Wierzbicki, London
16.05-16.15		Discussion		
16.15-16.35	3.2	PCSK9; background and scientific rational		P. Sever, London
16.35-16.45		Discussion		
16.45-17.05	3.3	PCSK9 inhibitors; trial progress to date		K. Ray, London
17.05-17.15		Discussion		
19.30		Drinks reception		
20.00		Conference Dinner		

PROGRAMME – FRIDAY 28 NOVEMBER, 2014

08.00 onwards		Registration		
Session 4		Lifelong CV risk	Chair:	P. Sever, London
08.30-08.45		Risk prediction, latest from JBS 3		K. Ray, London
08.45-08.50		Discussion		
08.50-09.05	4.2	Do new CVD biomarkers help in risk detection?		D. Preiss, Glasgow
09.05-09.10		Discussion		
09.10-09.25	4.3	Imaging atherosclerosis for risk prediction		A Lindsay, London
09.25-09.30		Discussion		
Session 5		Lipids in high risk patients	Chair:	S. Thom, London
09.30-09.50	5.1	Lipids and diabetes		A.S. Wierzbicki, London
09.50-10.00		Discussion		
10.00-10.20	5.2	Familial hypercholesterolaemia		M. Seed, London
10.20-10.30		Discussion		
10.30-10.50	5.3	Lipids and stroke prevention		N. Poulter, London
10.50-11.00		Discussion		
11.00-11.30		Coffee		
Session 6		Further management	Chair:	N.R. Poulter, London
11.30-11.45	6.1	Exercise and CVD		S. Thom, London
11.45-11.50		Discussion		
11.50-12.05	6.2	Non-alcoholic fatty liver disease		D. Preiss, Glasgow
12.05-12.10		Discussion		
12.10-12.25	6.3	HIV, treatment & consequences		C. Dawson, Birmingham
12.25-12.30		Discussion		
12.30-12.45	6.4	Lipids and the kidney		C. Baigent, Oxford
12.45-12.50		Discussion		
12.50-13.45		Lunch		

Session 7		Drugs, diets, hot topics	Chair:	K. Ray, London
13.45-14.00	7.1	Statin side effects, fact or fiction?		P. Sever, London
14.00-14.05		Discussion		
14.05-14.20	7.2	Saturated fats revisited		T. Sanders, London
14.20-14.25		Discussion		
14.25-14.40	7.3	Other lipid-lowering drugs on the horizon		P. Flynn, Cambridge
14.40-14.45		Discussion		
14.45-15.00	7.4	Soft drinks: adverse cardio-metabolic effects		G. MacGregor, London
15.00-15.05		Discussion		
Session 8		Case presentations	Panel:	P. Miller, K. Ray & P. Flynn
15.05-15.55	8.1	Case presentations from delegates and faculty		
15.55		Close of meeting		